Journal article
News at XI: moving beyond factor Xa inhibitors
Abstract
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications. Currently available DOACs include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor (F) Xa. A new class of DOACs is under development. These new DOACs, which include asundexian and milvexian, inhibit …
Authors
Fredenburgh JC; Weitz JI
Journal
Journal of Thrombosis and Haemostasis, Vol. 21, No. 7, pp. 1692–1702
Publisher
Elsevier
Publication Date
July 2023
DOI
10.1016/j.jtha.2023.04.021
ISSN
1538-7933